New Drug Application Withdrawn
Bristol-Myers Squibb Pulls Vanlev
PRINCETON, NJ- Vanlev, the first antihypertensive drug to receive priority review by the Food and Drug Administration (FDA), has been withdrawn from the approval process. Bristol-Myers Squibb voluntarily pulled the application due to questions raised by the FDA regarding a potential side effect. Though infrequent, the possibility of angioedema, a localized swelling affecting the face, throat, lips, or tongue, has been cited in some cases. Vanlev was designed to inhibit simultaneously two key enzymes, the angiotensin-converting enzyme (ACE) and neutral endopeptidase (NEP) that regulate blood pressure. Studies have shown that the drug significantly reduces both systolic and diastolic blood pressure. The company hopes to resubmit the application early next year after new data has been compiled.
From the Derby to the Decontam Room: Leadership Lessons for Sterile Processing
April 27th 2025Elizabeth (Betty) Casey, MSN, RN, CNOR, CRCST, CHL, is the SVP of Operations and Chief Nursing Officer at Surgical Solutions in Overland, Kansas. This SPD leader reframes preparation, unpredictability, and teamwork by comparing surgical services to the Kentucky Derby to reenergize sterile processing professionals and inspire systemic change.
Show, Tell, Teach: Elevating EVS Training Through Cognitive Science and Performance Coaching
April 25th 2025Training EVS workers for hygiene excellence demands more than manuals—it requires active engagement, motor skills coaching, and teach-back techniques to reduce HAIs and improve patient outcomes.
The Rise of Disposable Products in Health Care Cleaning and Linens
April 25th 2025Health care-associated infections are driving a shift toward disposable microfiber cloths, mop pads, and curtains—offering infection prevention, regulatory compliance, and operational efficiency in one-time-use solutions.
Phage Therapy’s Future: Tackling Antimicrobial Resistance With Precision Viruses
April 24th 2025Bacteriophage therapy presents a promising alternative to antibiotics, especially as antimicrobial resistance continues to increase. Dr. Ran Nir-Paz discusses its potential, challenges, and future applications in this technology.
